Regeneron Pharmaceuticals Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while iShares 0 3 Month Treasury Bond ETF trades at $100.5. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SGOV | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Fixed Income |
52-Week High | $852.03 | $100.72 |
52-Week Low | $555.51 | $100.28 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The ETF maintains consistent dividend distributions with recent payouts of $0.30-$0.31 per share. Technical indicators show strong bearish momentum with 17 sell signals versus 3 buy signals, though RSI levels suggest potential oversold conditions. Market sentiment reflects broader Treasury market concerns as rising oil prices fuel inflation worries.
The outlook remains cautious given the bearish technical picture and macroeconomic headwinds from rising Treasury yields. Investors seeking Treasury exposure may find value in SGOV's stability and dividend consistency, though the current environment of rising rates and inflation pressures presents near-term challenges for fixed income ETFs.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →